**TITLE PAGE**

**Article category**

Clinical guideline

**Title**

Society for Endocrinology guidelines for the treatment of male hypogonadism

**Authors**

Channa N. Jayasena1, Richard A Anderson2, Sofia Llahana3, Julian H. Barth4, Finlay MacKenzie5, Scott Wilkes6, Neil Smith7, Prasanna Sooriakumaran8, Sukhbinder Minhas9, Frederick C.W. Wu10, Jeremy Tomlinson11, Richard Quinton12

**Affiliations**

1Section of Investigative Medicine, Hammersmith Hospital, Imperial College London, London, UK

2MRC Centre for Reproductive Health, University of Edinburgh, UK

3School of Health Sciences, City, University of London, London & Department of Endocrinology& Diabetes, University College London Hospitals (UCLH) NHS Foundation Trust, London, UK

4Specialist Laboratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK

5University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

6School of Medicine, University of Sunderland, Sunderland, UK

7Patient member

8Department of Uro-oncology, UCLH NHS Foundation Trust, London & Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK

9Department of Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK

10Division of Endocrinology, Diabetes & Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

11Oxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, Oxford, UK

12Department of Endocrinology, Diabetes & Metabolism, Newcastle-upon-Tyne Hospitals NHS Foundation Trust & Translational & Clinical Research Institute, University of Newcastle-upon-Tyne, UK

**Corresponding authors**

Dr Channa N. Jayasena, Section of Investigative Medicine, 6th Floor Commonwealth Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK c.jayasena@imperial.ac.uk

ORCID: https://orcid.org/0000-0002-2578-8223

Dr Richard Quinton, Endocrine Unit, Leazes Wing - Level 6, Royal Victoria Infirmary, Queen Victoria Rd, Newcastle-upon-Tyne, NE1 4LP, UK Richard.Quinton@ncl.ac.uk

ORCID: https://orcid.org/0000-0002-4842-8095

**Conflicts of Interest Statement**

1CNJ: Speaker fees from Besins Healthcare

3SL: Speaker fees from Besins Healthcare, Pfizer UK, Ipsen Global and sponsorship for conference attendance from Bayer UK

8PS: Speaker fees from Janssen and Intuitive Surgical Inc., consultancy fees from Cambridge Medical Robotics

12RQ: Speaker fees and sponsorship for conference attendance from Bayer UK, and Speaker fee from Besins Healthcare and Sandoz UK

**Author Declaration**

Please see “Author Declaration Form-Jayasena et al 2021” file

**Funding Statement**

Contributors in this work receive research funding from the following:

1CNJ: National Institute for Healthcare Research (NIHR) Post-Doctoral Fellowship & Imperial NIHR Biomedical Research Centre;

1CNJ & 12RQ: NIHR Health Technology Assessment (HTA) Grant;

3SL: NIHR ICA Post-Doctoral Clinical Lectureship (SL);

8PS: Prostate Cancer Foundation Young Investigator Award.

**Data availability statement**

Data sharing and data accessibility is not applicable to this manuscript

**Summary**

Male hypogonadism (MH) is a common endocrine disorder. However, uncertainties and variations in its diagnosis and management exist. There are several current guidelines on testosterone replacement therapy (TRT) which have been driven predominantly by single disciplines. The Society for Endocrinology commissioned this new guideline to provide all care providers with a multidisciplinary approach to treating patients with MH. This guideline has been compiled using expertise from endocrine (medical and nursing), primary care, clinical biochemistry, urology & reproductive medicine practices. These guidelines also provide a patient perspective to help clinicians best manage MH.

**Key Words**

Hypogonadism, testosterone, libido, erectile dysfunction, guideline

**Word Count:** 9,692